Xtandi FDA approval - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Platinum Equity to acquire Energy Distribution Partners after 45 acquisitions and threefold EBITDA growth

Infographic showing Senores Pharmaceuticals Limited’s ₹43 crore manufacturing expansion in India and the United States, nearly 25% quarterly revenue growth, improved operating margins and a 14.4% share-price decline over two trading sessions.

Senores Pharmaceuticals (SENORES) targets 3.2bn annual manufacturing units, yet 50% to 70% utilisation raises a bigger question

People Inc added 320 employees this year. Why is it still cutting 195 jobs?

Infographic showing Aspen Neuroscience pricing its Nasdaq IPO at $15 per share, highlighting sasineprocel’s planned move into Phase 3 testing for Parkinson’s disease, operating runway into the second half of 2028 and the likelihood of additional capital needs.

Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase

Read More

Pharma Industry News

Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC

In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA)…

bypharmanewsdaily

July 14, 2018

web analytics